These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30137641)

  • 1. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
    Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
    Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
    Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
    Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
    Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
    Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of using genetically engineered biological drugs in children with a systemic form of JIA in the Karaganda region.
    Kenzhetaeva T; Kenzhetayeva Z; Meldebekova A; Batyrbekova L; Ablasano A; Zhumanova G
    Bratisl Lek Listy; 2023; 124(8):615-621. PubMed ID: 37218495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
    Kearsley-Fleet L; Davies R; Baildam E; Beresford MW; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2016 Sep; 55(9):1556-65. PubMed ID: 26732349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
    Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
    J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
    Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
    Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
    Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
    Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
    Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis.
    Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D
    Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
    Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
    Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.